RxDoctor Payments Data

Melisa Wilson, APRN

Acute Care · Orlando, FLNPI 1780618355

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (53.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by United Therapeutics Corporation at 41.2% of the total. Among acute care clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$214,028in general payments, 2019–2025

Across 430 payments — averaging $497.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • United Therapeutics Corporation$88K
  • Actelion Pharmaceuticals US, Inc.$79K
  • Merck$20K
  • Actelion Pharmaceuticals, Ltd$13K
  • Bayer$10K
  • Johnson & Johnson$3K
  • plus $653 from 7 others
$3,404,615in research payments, 2019–2025

Across 37 payments — averaging $92,017 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$3.4M
  • United Therapeutics Corporation$33K

What the payments were for

  • Consulting fees$47,74422%
  • Speaking & faculty fees$114,78254%
  • Travel & lodging$40,24419%
  • Food & beverage$11,1945%
  • Education$640%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$214,028 in reported general payments places this provider in the 95th percentile of 1,150 acute care providers in Florida.

See all acute care providers in Florida

Medicare billing

Part B allowed, 2024
$4,844
Medicare patients
60
Services billed
86

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Orenitram ErTreprostinil Diolamine17$604,221
WinrevairSotatercept-Csrk13$237,985
OpsumitMacitentan12$154,407

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckWinrevair$20,107$237,98513 claims
Actelion Pharmaceuticals US, Inc.Opsumit$79,011$154,40712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,150 acute care providers in Florida.

Other acute care in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →